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ABSTRACT

Lameness poses a substantial challenge to the horse industry, costing millions
of dollars per year in treatments, labor, and loss of use of performance horses.
Osteoarthritis is a leading cause of chronic lameness. Treatments that stimulate
cartilage development may promote cartilage healing. Many current treatment
options for osteoarthritis have limited effectiveness and are expensive. Bovine
supramammary lymph nodes are widely available at no cost and contain bioactive
growth factors that could promote cartilage healing. The purpose of this study was
to determine the proliferative effect of bovine lymph node extract on equine
chondrocytes in vitro.
Equine chondrocytes were harvested from the scapular cartilage of adult
horses. Lymph node extract (LNE) was prepared by mixing freeze-dried lymph
node powder with PBS followed by heat inactivation. Chondrocytes were cultured
in vitro, first in DMEM with 10% bovine growth serum (BGS) and antibiotics,
then with treatment media containing either BGS or LNE on equal and unequal
protein bases. Additionally, LNE fractions from ammonium sulfate precipitation
were examined as BGS replacements. The response of the cells to IGF-I and
TGF- was also examined. DNA accumulation was measured using the
CyQUANT DNA assay as a means to quantify cell stimulation, i.e. growth.
When BGS and LNE were compared on equal and unequal protein basis over a
range of protein concentrations, there were no statistically significant differences

observed in proliferation between BGS– and LNE– treated cells. However, in a
separate experiment, cells treated with LNE had significantly higher cell
proliferation than cells treated with BGS or different LNE fractions. IGF-I and
TGF- had no significant effects on cell proliferation.
Overall, the results indicate LNE is capable of stimulating chondrocyte
proliferation to an equal or greater degree than BGS, suggesting LNE could
promote cartilage healing. Further studies are needed to determine if LNE can be
used to develop new therapies for osteoarthritis in horses.
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INTRODUCTION
Lameness poses a substantial challenge to the horse industry. A recent national
study showed that the economic cost due to lameness in America per year ranged
from $678 million to $1 billion (APHIS 2001). Two-thirds of incurred cost comes
solely from loss of use of horses, with the rest attributable to veterinary bills and
additional treatment costs. A separate study showed that approximately 67% of
lame horses are chronically lame, that is, lame for 4 months or longer (NAHMS
2000). Ongoing treatment costs, loss of use of affected horses, and time spent
treating chronically lame horses can lead to a considerable investment in time and
money. Lameness can be considered the most significant factor contributing to
loss of performance, with over 67% of days lost being due to lameness (Rossdale
et al., 1985). Although lameness can be attributed to many factors, osteoarthritis
can be considered one of the most economically important because of its
prevalence and variety of causes (Auer and Fackelman, 1981). Todhunter and
Lust (1990) estimate that 42% of lameness is directly related to joint disease.
Osteoarthritis is a degenerative joint disease characterized by degeneration of
articular cartilage. Osteoarthritis can cause a tremendous amount of pain and
restricted motion in the affected joints, severely limiting the horse’s athletic
potential and negatively impacting welfare. Although cartilage degeneration
occurs naturally with age, it occurs much faster when the joints are subject to high
levels of stress. In performance horses, osteoarthritis commonly occurs in knees,
hocks, and fetlocks – all joints that undergo substantial wear and tear during

strenuous exercise. The articular cartilage is gradually destroyed via chondrocyte
apoptosis and subsequent matrix degradation, and it cannot be regenerated
quickly in adult horses. Osteoarthritis is becoming more common in younger,
hard-working horses and can severely limit the horses’ useful working careers.
Currently, there is no cure for osteoarthritis. There are, however, a variety of
treatments that have proven to be fairly effective. These include non-steroidal
anti-inflammatory drugs (NSAIDs) such as phenylbutazone (bute) and
corticosteroids, which both serve to reduce inflammation and relieve pain. Other
treatments include polysulfated glycosaminoglycans (PSGAGs) and
nutraceuticals, such as glucosamine and chondroitin sulfate. The treatments
attempt to prevent further cartilage degradation. Hyaluronic acid is also
commonly used as a lubricant to reduce the effects of depleted cartilage and to
prevent further damage.
Unfortunately, none of the above options can provide a cure for osteoarthritis.
Most of these treatments are not used until the cartilage is already degraded and
the horse is in pain. Many treatments have negative side effects which accumulate
with long-term use. For example, NSAIDs such as phenylbutazone can lead to the
development of gastric ulcers, if given in high doses for an extended period of
time, and may also cause decreased proteoglycan synthesis in articular cartilage.
Numerous studies have suggested that prolonged use of corticosteroids, while
effective for reducing inflammation and pain, may cause detrimental effects on
the biochemical composition and morphological features of cartilage. NSAIDs,
corticosteroids, PSGAGs, and nutraceuticals must all be used either continuously
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or on a regular basis if the effects are to be maintained and these treatments can be
quite expensive. New options such as gene transfer and the use of autologous cell
transplantation are being explored. However, these therapies could potentially be
very expensive and not readily available to the average horse owner even if the
techniques were possible, thereby necessitating the development of better and
more cost-effective treatments.
The focus of this research is to examine the proliferative response of equine
chondrocytes to bovine mammary lymph node proteins. Bovine supramammary
lymph nodes contain cytokines and growth factors and are available in large
quantities at very low cost. If nodal proteins are capable of stimulating equine
chondrocyte proliferation and matrix synthesis, they could potentially be used as
the basis for an effective treatment for osteoarthritis that could be made widely
available at relatively low cost.

Rationale
Bovine serum is commonly used as a supplement in cell culture media.
Previous research has indicated that bovine serum is capable of supporting
chondrocyte proliferation and maintenance of phenotype in vitro. Kolettas et al.
(1995) showed that chondrocytes cultured long-term in medium supplemented
with 10% fetal bovine serum (FBS) were able to retain their differentiated
phenotype. Chaipinyo et al. (2002) found that chondrocytes cultured in medium
containing 20% FBS showed equal proliferation and similar protein synthesis to
chondrocytes receiving serum-free medium containing IGF-I, TGF-, and bFGF.
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Finally, chondrocyte viability, cell density, and proteoglycan synthesis after longterm storage was found to be much greater if the chondrocytes were stored in
medium containing 10% FBS rather than in serum-free medium (Pennock et al.,
2006). An alternative source of bovine proteins may be able to support cell
growth and metabolism to the same degree as serum. Bovine lymph nodes may be
able to serve as an adequate alternative source of bovine proteins.
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LITERATURE REVIEW
Characteristics of articular cartilage
Articular cartilage is found covering the surfaces of diarthroidial joints in the
body, providing cushioning and preventing excessive wear and tear of joint
surfaces. It is made up exclusively of hyaline cartilage, which is the most
common type of cartilage found in the body. Hyaline cartilage usually is covered
by a layer of dense connective tissue called the perichondrium, which plays an
important role in cartilage growth and maintenance; however, the hyaline
cartilage found in articular cartilage lacks perichondrium. Instead, it is supported
by nutrients brought in by the synovial fluid circulating between joint surfaces.
Articular cartilage is avascular and thus undergoes primarily anaerobic
metabolism.
Articular cartilage is not homogenous; instead it contains three distinct zones –
superficial, intermediate, and deep. The cells and matrix found in each zone are
homogenous within a zone and heterogeneous between zones. Differences in
morphology, metabolic activity, and gene expression may be observed
(Chubinskaya et al., 2003).

Cells
The cellular unit of articular cartilage is the chondrocyte. Chondrocytes are
differentiated cells of mesenchymal origin. They make up approximately 5-10 %
of the total cartilage volume. Chondrocytes tend to exist in groups of up to eight

cells, called isogenous groups. Isogenous groups are separated from each other in
matrix cavities called lacunae. As a result, chondrocytes must communicate with
each other via the extracellular matrix. Chondrocytes produce and maintain the
extracellular matrix, as well as producing growth factors involved in normal
anabolic and catabolic reactions in the cartilage. The action of chondrocytes is
influenced by existing matrix composition, mechanical load, hormones, growth
factors, cytokines, aging, and injury (Ulrich-Vinther et al., 2003).

Fiber
Articular cartilage is built on an extensive scaffold of collagen fibrils. Fibrils,
containing many glycine, proline, and hydroxyproline residues, are formed by
three amino acid chains wrapped together to form a left-hand helix. Articular
cartilage contains predominantly collagens type II, IX, and XI (Mendler et al.,
1989). Type II collagen, discovered by Miller and Matukas in 1969, is the primary
collagen type found in articular cartilage, making up 90-95% of the total collagen
and at least 50% of the dry weight of the cartilage. Type II collagen is found
almost exclusively in articular cartilage and thus is often used as a marker for the
differentiated chondrocyte phenotype. The presence of type I collagen has often
been considered a marker of chondrocyte dedifferentiation; however, studies have
shown that differentiated chondrocytes do produce small amounts of collagen I
(Kolettas et al., 1995). Collagen types IX and XI are present in much smaller
amounts but are essential for collagen cross-linking, which stabilizes the fibrils
and provides structural integrity. Collagen XI may also regulate the fibril diameter
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of type II collagen (Ulrich-Vinther et al., 2003). Collagen fibril arrangement
differs in the three cartilage zones. Fibrils are aligned parallel to the cartilage
surface in the superficial layer and perpendicular to the cartilage surface in the
deep layer, with the fibrils forming arches in the intermediate layer. Benninghoff
(1925) described this arrangement as a Gothic arch (Zambrano et al., 1982).
Collagen primarily provides structural support but may play an important role
in the composition of the extracellular matrix produced by chondrocytes (Qi and
Scully, 2003). Collagen fibrils undergo slow metabolism and have a very long
lifespan. However, in disease states, turnover may increase rapidly and exceed the
chondrocyte’s ability to produce matrix, leading to matrix deterioration and
failure (Ulrich-Vinter et al., 2003). As a result, and also because the structural
support provided by collagen is necessary for proper cartilage function, collagen
fibrils are a major target of cartilage degeneration (Aigner and Stove, 2003).

Matrix
The extracellular matrix consists of the above mentioned collagen fibers and
aggregating proteoglycans. Aggrecan is the primary proteoglycan found in
articular cartilage. It is a large molecule made of chondroitin sulfate and keratan
sulfate chains bound to a protein core. Aggrecan is capable of binding noncovalently to hyaluronic acid and forming aggregates up to several hundred
million Daltons in size. Link protein stabilizes the bond between aggrecan and
hyaluronic acid by binding both simultaneously and decreasing the dissociation
constant, making the bond much less likely to dissociate under normal
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physiological conditions (Todhunter, 1996). Proteoglycan aggregates have a
negative charge and thus attract cations. The increased osmolality in the tissue
attracts water, which accounts for approximately 75% of the weight of articular
and also gives cartilage unique biochemical properties. The water causes a high
tissue pressure but collagen fibers prevent swelling and provide rigidity. One of
the earliest changes in osteoarthritis involves loss of integrity of the collagen
fibrils, which leads to swelling and loss of proteoglycans from the matrix (UlrichVinther et al., 2003). Cartilage also contains many smaller proteoglycans such as
decorin, fibromodulin, and others which bind to other molecules such as collagen
II and help stabilize the matrix.
Interactions between chondrocytes and the extracellular matrix are vital for
biological processes such as growth, differentiation, and matrix synthesis and
degradation. An understanding of the interface through which the chondrocyte
and surrounding matrix interact may provide insight into the pathogenicity of
osteoarthritis (Lapadula and Iannone, 2005). Integrins are the primary cell surface
receptors responsible for chondrocyte-matrix attachment complexes that allow
communication between the chondrocyte and its surrounding matrix (Svoboda,
1998). In particular, the  family of integrins is thought to mediate chondrocyte
interaction with collagen types I and II and fibronectin (Motomi et al., 1993).

Synovium
The synovium lines the joint capsule and includes a layer of connective tissue
and a layer of cells, synoviocytes, with no basement membrane. Type A
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synoviocytes have phagocytic and immune function; type B synoviocytes are
secretory, synthesizing the hyaluronan and lubricin found in synovial fluid.
Synovial fluid acts as the medium of exchange between blood and the avascular
articular cartilage, and also helps provide lubrication for the joint (Junqueira and
Carneiro, 2005). There are two types of joint lubrication (Todhunter 1996). The
first, often referred to as boundary lubrication, is provided by hyaluronan and
lubricin in synovial fluid, which are highly viscous and move over the surface of
the joints, causing a low coefficient of friction. The second type of lubrication is
known as weeping lubrication, which is exudation of fluid from the cartilage itself
when under compression. This fluid also decreases the coefficient of friction due
to the incompressible nature of fluids, which provides a small bit of space
between articulating surfaces.

Articular cartilage growth and development
Articular cartilage develops from mesenchymal stem cells. Mesenchymal stem
cells (MSCs) are capable of differentiating into a variety of cell types such as
chondrocytes, osteoblasts, and adipocytes, as well as muscle, tendons, ligaments,
dermis, etc. Each cell type follows a unique pathway with specific conditions for
initial differentiation and its own set of local cues required for lineage
progression. Manipulation of the cells or the culture conditions can alter the
pathway, leading to differentiation of different cell types (Caplan, 1991).
Articular cartilage is thought to grow appositionally, i.e. from the articular
surface. Archer et al. (1994) used antibodies to detect proliferating chondrocytes
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and chondrocytes synthesizing IGF-1 and -2 and IGF binding protein in young
marsupials and found that as the animals aged, these chondrocyte populations
became more restricted to the articular surface, providing supporting evidence for
an appositional growth mechanism. In a similar study by Hayes et al. (2001),
antibodies against TGF- isoforms were used and the results supported those
obtained in Archer’s study. In addition, Dowthwaite et al. (2004) was able to
identify a progenitor cell population on the surface of articular cartilage, lending
further support to the appositional growth mechanism theory. Differentiated
chondrocytes have been shown to have the ability to dedifferentiate and act as
progenitor cells themselves. Cells of chondrogenic, osteogenic, adipogenic,
myogenic, and neurogenic lineages have all been produced from dedifferentiated
human articular chondrocytes in vitro (Tallheden et al., 2003; Fuente et al., 2004).
In addition to the multipotent cells found in cartilage itself, multipotent
mesenchymal cells from other nearby locations can also differentiate and undergo
chondrogenesis. Bone marrow-derived mesenchymal cells have been used
successfully for chondrogenesis both in vitro and in vivo. Chen et al. (2005) were
able to remove MSCs from sheep, culture them in a 3-D scaffold, and then
implant them back into the joint cavity where they were able to express collagen
II and synthesize sulfated proteoglycans. In addition, MSCs cultured in synovial
fluid in vitro were also able to undergo chondrocytic differentiation, suggesting
the synovial fluid is important in promoting the chondrogenic lineage.
Cells harvested from the synovial membrane have also been shown to possess
properties of multipotent mesenchymal cells. These cells are able to proliferate
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extensively and maintain their multilineage differentiation potential in vitro.
Cultured cells from the human synovial membrane were able to differentiate into
chondrocytes, osteocytes, and adipocytes under appropriate culture conditions (De
Bari et al., 2001). Some studies have also suggested that cells from the periosteum
may exhibit chondrogenic potential (O’Driscoll et al., 1994). However, in a study
by Brittberg et al. (2005) in which chondrocytes were co-cultured with periosteal
tissue, the periosteum was found to play an important role in stimulating
chondrocyte growth and differentiation but periosteal tissue itself did not exhibit
chondrogenic potential.

Growth factors involved in articular cartilage metabolism
Bone morphogenetic proteins
Bone morphogenetic proteins are members of the transforming growth factor 
superfamily. BMPs 1, 2, 4-6, and 11 are present in fetal, adult, and osteoarthritic
cartilage, while BMPs 7 and 8 are only present in fetal cartilage and BMPs 9 and
10 only present in osteoarthritic cartilage (Chen et al., 2004). BMPs play an
important role in commitment to the chondrogenic lineage and maintenance of
chondrocyte phenotype. Enomoto-Iwamoto (1998) transfected cultured chick
embryo chondrocytes with dominant negative BMP receptors, which bind BMPs
but do not transmit further signals, and found increased cell proliferation, a more
fibroblastic morphology, and decreased production of collagen II and aggrecan,
suggesting that BMPs are required for maintenance of chondrocyte phenotype and
control of cell proliferation. Human multipotent mesenchymal cells cultured in
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the presence of BMPs-2 and -9 express collagen II and increased levels of
aggrecan, suggesting chondrocytic differentiation. These chondrocytes showed
increased expression of Sox-9 transcription factor, which regulates collagen II and
aggrecan expression (Majumdar et al., 2001). Park et al. (2005) found similar
results when bovine synovial progenitor cells were cultured with supplemental
BMP-2. Bovine chondrocytes cultured long-term in the presence of BMP-2
maintained increased production of collagen II and aggrecan compared to controls
and did not undergo hypertrophy (Sailor et al., 1996). Treatment with BMP-7
(osteogenic protein-1) has also been shown to enhance production of aggrecan
and hyaluronan in bovine full-thickness cartilage slices (Nishida et al., 2000) and,
when placed in a collagen carrier and implanted into full-thickness cartilage
defects in dogs, was able to induce cartilage repair (Cook et al., 2003). Hills et al.
(2005) showed that BMP-9 was able to induce increased collagen and
proteoglycan synthesis in cultured juvenile bovine chondrocytes but did not seem
to have a significant effect on adult chondrocytes.

Insulin-like growth factor I
Insulin-like growth factor I (IGF-1) is another growth factor influencing
articular cartilage metabolism. IGF-1 affects almost every cell in the body,
playing a vital role in normal physiology and growth and development. In
articular cartilage, IGF-1 promotes matrix synthesis and cell proliferation,
providing a counterbalance against cytokines such as interleukin I-which are
responsible for cartilage breakdown.
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IGF-1 has been shown to help maintain the chondrocyte phenotype in cultured
bovine chondrocytes in a 3D matrix (Chaipinyo et al., 2002) and is able to
increase collagen II and aggrecan gene expression in the growth zone of goat
chondrocytes cultured in monolayer (Darling and Athanasiou, 2005). Along with
TGF-, IGF-1 is also able to stimulate chondrogenesis from bone marrow
(Worster et al., 2001) and periosteal mesenchymal stem cells (Fukumoto et al.,
2003), with the cultured MSCs exhibiting increased proliferation and production
of collagen II and aggrecan, although not to the degree of fully differentiated
chondrocytes. IGF-1 is also useful in expansion and redifferentiation of
chondrocytes used in tissue engineering. Especially when using autologous
chondrocyte transplantation, chondrocytes must first undergo proliferation, during
which they often lose their phenotype, and then must redifferentiate before being
transplanted into the joint. Pei et al. (2002) found that after chondrocytes were
expanded in monolayer, subsequent culture with supplemental IGF-1 yielded
constructs with high levels of glycosaminoglycans and collagen II. Additionally,
IGF-1 plays a role in preventing articular cartilage damage caused by mechanical
injury and cytokines. Bovine and human cartilage explants cultured with
supplemental IGF-1 after exposure to mechanical injury showed a significant
decrease in apoptosis compared to explants cultured without IGF-1 (D’Lima et
al., 2001). IGF-1 was also able to increase net proteoglycan synthesis in cultured
porcine chondrocytes, even in the presence of interleukin 1 and other cytokines
(Tyler, 1989).
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Transforming growth factor
Transforming growth factorplays a significant role in promoting cartilage
anabolism both in vitro and in vivo. TGF-is most often used in concert with
other growth factors such as insulin-like growth factor 1 or basic fibroblast
growth factor. Rabbit articular chondrocytes cultured with supplemental TGF-
show marked increases in collagen and glycosaminoglycan production but little
change in cell proliferation (Redini et al., 1988). Numerous other studies,
reviewed by Grimaud et al. (2002), have found the effects of TGF- in vitro and
in vivo to vary depending on environmental conditions. In addition, cell response
to TGF- supplementation in vivo seems to depend on length of exposure, with
short-term exposure having the positive benefits mentioned above but long-term
exposure leading to disruption of cartilage homeostasis and ultimately cartilage
destruction.
When used in combination with other growth factors, TGF- contributes
significantly to the overall stimulation of cartilage matrix synthesis. Darling and
Athanasiou (2005) found that when cultured goat chondrocytes were
supplemented with IGF-1, bFGF, and TGF-, TGF- had the greatest effect on
cell proliferation and was able to stimulate protein expression, collagen II
production, and glycosaminoglycan secretion in both the superficial and growth
zones. Also, cultured bovine chondrocytes exposed to TGF-, IGF-1, and bFGF
exhibited similar proliferation rates and amount of protein synthesized as
chondrocytes supplemented with 20% fetal calf serum; however, proteoglycan
production was much lower in the serum-free group (Chaipinyo et al., 2002).
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In addition to exerting positive effects on chondrocyte proliferation and matrix
production, TGF- is able to affect chondrocyte differentiation and promote
chondrogenesis of mesenchymal stem cells. Studies by Jakob et al. (2001) and Pei
et al. (2002) showed articular chondrocytes cultured in monolayer with
supplemental TGF- and FGF-2 had enhanced proliferation rates and increased
dedifferentiation. However, these chondrocytes were easily induced to
redifferentiate when exposed to IGF-1 or when transferred to a 3D matrix with
supplemental growth factors. Chondrocyte dedifferentiation induced by TGF/FGF-2 showed by far the greatest amount of redifferentiation when exposed to
these same growth factors rather than other growth factors once cultured in a 3D
matrix (Jakob et al., 2001). Worster et al. (2001) also found that cultured equine
MSCs from bone marrow supplemented with TGF- exhibited increased
proliferation, development of a rounded morphology, and somewhat increased
proteoglycan content; however, MSC differentiation was not complete when
compared to mature chondrocytes and TGF- had less effect on the MSCs than
did IGF-1.
Interleukin-1
Articular function relies on a balance of matrix synthesis and destruction.
While the above-mentioned and many other growth factors are responsible for
cartilage anabolism, cytokines such as interleukin-1 (IL-1) are responsible for
matrix degeneration and are often involved in the pathogenesis of osteoarthritis.
Chondrocytes from osteoarthritic patients have increased levels of cytokines,
including IL-1 (Shinmei et al., 1991). Chondrocytes cultured in the presence of
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IL-1show increased production of matrix metalloproteinases and release of
proteoglycans from the matrix (Shinmei et al., 1989). IL-1 may also play a role in
linking mechanical trauma to decreased proteoglycan synthesis. Murata et al.
(2003) showed when compressed cartilage explants were cultured in the presence
of IL-1 receptor antagonist, the decrease in proteoglycan synthesis was
minimized, suggesting that IL-1 is in some way responsible for the decrease in
proteoglycan synthesis that occurs following mechanical compression.

Impact of mechanical force on articular cartilage
Mechanical factors play a very important role in the development,
maintenance, and degeneration of articular cartilage. Articular cartilage requires
intermittent hydrostatic pressure to maintain its phenotype and prevent continuing
endochondral ossification leading to osteoarthritis (Carter et al., 2004). Low
amplitude dynamic compression of bovine cartilage explants increases protein
and proteoglycan synthesis and accelerates the biosynthetic response to IGF-1,
with the combined anabolic result being much greater than either compression or
IGF-1 alone (Bonassar et al., 2001). However, excessive trauma to the joints can
lead to the breakdown of articular cartilage and allow the early onset of
osteoarthritis.
Osteoarthritis is caused by cartilage degeneration, which occurs when the
balance of matrix synthesis and degradation is disrupted. Mechanical trauma can
disrupt this balance by causing cell death, loss of proteoglycans, or damage to
collagen integrity. Numerous studies utilizing full-thickness cartilage explants

16

have shown that mechanical compression leads to chondrocyte apoptosis which
increases in a dose-dependent manner with increasing peak stress levels (Loening
et al., 2000; D’Lima et al., 2001; D’Lima et al., 2001; Patwari et al., 2004).
Although there is some thought that chondrocyte apoptosis may be the cause of
loss of matrix integrity following injury, Loening et al. (2000) found apoptosis to
occur at stresses lower than that required to cause matrix degradation, measured
by glycosaminoglycan (GAG) release into the media, suggesting apoptosis may
be simply one of the earliest responses to injury without actually causing any
subsequent matrix degeneration or altered biochemical response. However, a high
degree of apoptosis is obviously not going to promote cartilage integrity. One
particular study exposed the 2mm center of 4mm cultured cartilage discs to cyclic
impact and found that when chondrocytes in impacted regions undergo apoptosis,
they send a signal, perhaps nitric oxide or a cytokine such as IL-I throughout the
unimpacted regions nearby, causing formerly unaffected chondrocytes to undergo
apoptosis as well (Levin et al., 2001). The induced apoptosis of unimpacted cells
could have potentially much more damaging effect on the cartilage than just the
effect from mechanical trauma. In addition to cell death, repeated mechanical
trauma has been shown to disrupt the collagen framework of bovine articular
cartilage explants (Broom, 1986) and strenuous exercise in young horses has
resulted in damage and loosening of the collagen framework in the fetlock joint
(Brama et al., 2000). Since the collagen fibrils provide the structure that entraps
proteoglycans and prevents swelling due to water content, a disruption in the
collagen network leads to loss of proteoglycans from the matrix and increased
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water content of the cartilage. Torzilli et al. (1999) showed that subjecting bovine
articular cartilage explants to nominal impact stresses resulted in decreased
proteoglycan synthesis and increased water content, and at high enough stress,
cell death and rupture of the collagen fibril matrix. Proteoglycan turnover is fairly
fast and depends a great deal on environmental conditions; however, collagen
turnover is very slow, thus damage to the collagen framework can pose a more
serious problem.
The effects of mechanical trauma depend on several factors such as peak
stress, rate of loading, and duration of loading. Bovine and canine articular
cartilage explants exposed to greater peak stress levels and higher rates of loading
or stress rates showed increase cell death and matrix damage, as indicated by
altered proteoglycan synthesis, release of GAGs into the media, and cracks in the
tissue (Chen et al., 1999; Ewers et al., 2001; Quinn et al., 2001). These
experiments indicated high rates of loading can lead to visible cracks in the
superficial zone and increased cell death near the cracks, although lesser rates of
loading can still cause cell death even if unaccompanied by visible surface
damage. Longer duration of loading can also cause increased damage that persists
longer. Overall, the extent of injury and patterns of damage vary depending on the
nature of the load applied.

The influence of aging on articular cartilage
Aging and osteoarthritis are often considered to go hand in hand. Cartilage
degradation naturally occurs with aging due to the additive effects of trauma and
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also due to endochondral ossification which dramatically slows down at skeletal
maturity but never ceases completely. Loeser et al. (2000) examined chondrocytes
from joints of primates of various ages and found that osteoarthritis does not
always accompany aging; however, there are several factors caused by aging that
can encourage the development of osteoarthritis. One of the most noticeable
responses due to aging is a decreased response to IGF-1. Cartilage explants from
steers were found to synthesize less protein and proteoglycans than cartilage
explants from immature calves when stimulated with the same concentrations of
IGF-1 (Barone-Varelas et al., 1991). Because of the importance of IGF-1 in
maintaining the chondrocyte phenotype and synthesis of matrix components, a
decrease in response to IGF-1 disrupts the balance between matrix synthesis and
degradation, which ultimately can lead to osteoarthritis. Why this age-related
decrease in IGF-1 sensitivity occurs is still under debate. Martin et al. (1997)
observed that cultured rat chondrocytes from older rats exhibited decreased
proteoglycan synthesis and increased expression of IGF binding protein,
suggesting decreased response to IGF-1 with aging may be linked to increasing
levels of IGF binding protein. However, Loeser et al. (2000) showed that cultured
rat chondrocytes showed decreased response with aging to both IGF-1 and des(13) IGF-1, with the latter having the same ability to stimulate the IGF receptor but
decreased affinity for IGF binding protein. These results suggest the IGF receptor
may play a larger role than IGF binding protein, perhaps by age-related changes
in the IGF receptor or alterations in the intracellular signaling pathway by which
IGF exerts its effects. Messai et al. (2000) showed that age-related decrease in
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response of cultured rat chondrocytes to IGF-1 was correlated with decrease in
IGF-1-induced cAMP production and protein kinase C activation, further
supporting the idea of decreased ability of the chondrocyte to properly transduce
downstream signaling.
Chondrocyte senescence has also been proposed as a factor linking aging and
osteoarthritis. After a lifetime of being exposed to mechanical stress,
chondrocytes may accumulate oxidative damage that causes them to senesce
(Martin et al., 2004). The number of senescent chondrocytes increases with age
and the senescent cells may not be able to adequately maintain and repair the
articular cartilage (Martin and Buckwalter, 2001; Martin and Buckwalter, 2003).
However, it has been shown that cultured chondrocytes taken from older or
osteoarthritic patients can begin proliferating and synthesizing matrix components
under the right environmental conditions, even if these activities had ceased in
vivo.

Current therapies for osteoarthritis
Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen,
indomethacin, diclofenac, naproxen, dexamethasone, and phenylbutazone are
widely used to treat the symptoms of osteoarthritis, primarily because they
provide pain relief and many can be easily obtained over the counter. However,
there is evidence to suggest the use of NSAIDS, especially long-term use, may
inhibit cartilage repair processes. Dingle (1991) showed that adding NSAIDS to
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cultured porcine and human cartilage samples inhibited proteoglycan synthesis
and reduced the ability of the cartilage to recover from treatment with IL-1.
Phenylbutazone, the most commonly used treatment for osteoarthritis pain in
horses, has been shown to inhibit proteoglycan synthesis almost to the same
degree as exposure to IL-1 in articular samples taken from healthy horses
(Beluche et al., 2001). In vivo injections of various NSAIDS have been shown to
introduce morphological changes leading to degeneration in articular cartilage and
subchondral bone in knee joints of rabbits and hens (Kalbhen, 1989). Thus, while
these drugs may be effective in reducing inflammation associated with
osteoarthritis, their use may actually exacerbate the condition. In addition,
NSAIDs may have other undesirable side effects such as gastric ulcers. Many
studies, including MacKay et al. (1981) and Monreal et al. (2004), show that high
doses of phenylbutazone administered orally to horses for as little as two weeks
caused gastric ulcers and other serious side effects. However, these studies all
used much higher doses of phenylbutazone than is recommended for daily use in
the treatment of osteoarthritis.

Corticosteroids
Corticosteroids are commonly used in the treatment of osteoarthritis because
of their potent anti-inflammatory properties, although there is still much debate
concerning their use. Human osteoarthritic patients given intra-articular injections
of corticosteroids reported significant decrease in pain lasting up to 8 weeks postinjection. However, by 4 weeks post-injection, there was no significant difference
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between treated and placebo groups (Friedman and Moore, 1980). Numerous
studies have also indicated that intra-articular steroid injections can damage the
integrity of articular cartilage. In 1976, Gibson et al. studied the effects of intraarticular steroid injections on primate cartilage. The results showed no difference
in the joint structure between treated and control groups, which provided striking
contrast to many earlier studies showing deleterious effects of steroid injections.
Nevertheless, studies continue to support the idea that intra-articular steroid
injections may damage articular cartilage. Fubini et al. (2001) showed that
chondrocytes taken from young healthy horses and cultured in the presence of
corticosteroids had decreased synthesis of collagen II and the fibronectin (V+C)isoform, both of which are markers of the chondrocyte phenotype. Intra-articular
steroid injections also led to decreased strength, permeability, and thickness in
articular cartilage of exercised horses (Murray et al., 1998). There is some
thought that the effects of corticosteroids on articular cartilage may vary
depending on whether the joints tested are normal or osteoarthritic. Todhunter et
al. (1998) induced acute synovitis in ponies and then treated half with
corticosteroids. There was no difference in protein or proteoglycan synthesis
between treated, untreated, and control groups. However, when normal joints
were injected with corticosteroids, there was a significant decrease in
proteoglycan synthesis and increase in protein synthesis when compared to the
three aforementioned groups.
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Glucosamine and chondroitin sulfate
Glucosamine and chondroitin sulfate are both important components of
articular cartilage proteoglycans, and as such, are often used to treat the symptoms
of osteoarthritis. Numerous studies, reviewed by Brief et al. (2001), have shown
that the use of glucosamine and chondroitin sulfate leads to decreased pain and
tenderness, increased mobility, and sustained improvements after drug withdrawal
in patients suffering from osteoarthritis. These compounds are thought to have
chondroprotective properties, making them more useful than simple antiinflammatory agents in the treatment of osteoarthritis. Bassler et al. (1998) found
that articular chondrocytes taken from osteoarthritic patients and cultured in the
presence of glucosamine sulfate showed increased production of proteoglycans
but no change in DNA synthesis or collagen II production. A more recent study
by Dodge and Jimenez (2003) showed that glucosamine sulfate stimulates the
production of aggrecan mRNA and inhibits the production and activity of matrix
metalloproteinase-3 in cultured chondrocytes taken from osteoarthritic patients,
although chondrocytes taken from some patients did not respond at all to
glucosamine sulfate. Glucosamine HCl was also able to reduce induced cartilage
degradation in equine cartilage explants cultured with lipopolysaccharide or
recombinant human IL-1 (Fenton et al., 2000). In vivo, oral glucosamine
supplements given to rabbits were able to partially reduce articular degradation
caused by anterior cruciate ligament transection (ACLT), as evidenced by
decreased loss of proteoglycans and less histologic evidence of disease in the
treatment group (Tiraloche et al., 2005). Additionally, human osteoarthritic
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patients receiving oral glucosamine supplements showed no continued lessening
of joint space width after beginning treatment (Reginster et al., 2001).

Hyaluronic acid
Hyaluronic acid is a major component of synovial fluid and, along with
lubricin, helps provide lubrication for the joints. Additionally, each hyaluronic
acid chain is capable of binding many molecules of aggrecan and thus is essential
for maintaining the large proteoglycan aggregates that remain entrapped in the
collagen network and provide cartilage with its unique properties. Because of its
vital role in articular cartilage function, hyaluronic acid is commonly used as a
treatment for osteoarthritis.
Auer et al. (1980) found that intra-articular injections of hyaluronic acid in
horses with experimentally induced and naturally occurring osteoarthritis resulted
in decreased lameness and improved performance. Lameness was measured using
force plates to determine the amount of weight the horses were willing to bear on
each leg before and after treatment. Using the similar methods, Gingerich et al.
(1981) found that a single injection of 20 or 40 mg of hyaluronic acid into the
intercarpal joints of horses with experimentally induced osteoarthritis was able to
restore normal joint function, with functional improvement evident within one
week after treatment. Hyaluronic acid has also been shown to stimulate
proteoglycan synthesis in equine cartilage explants (Frean et al., 1999) and
significantly reduce chondrocyte apoptosis and nitric oxide production in rabbits
with osteoarthritis induced by anterior cruciate ligament transection (Diaz-
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Gallego et al., 2005). Numerous other clinical studies in animals and humans,
reviewed by Goldberg and Buckwalter (2005), have shown that injections of
hyaluronic acid prevent cartilage destruction following experimental induction of
osteoarthritis, help promote tissue repair and cartilage metabolism, and reduce
joint space narrowing caused by osteoarthritis.

Gene therapy
Another treatment option currently being explored is gene therapy. Because
osteoarthritis typically occurs when the balance between matrix production and
breakdown is disrupted, controlling the cellular factors that are responsible for
these changes may prove beneficial. Frisbie and McIlwraith (2000) used
adenoviral mediated gene transfer to cause over-expression of interleukin-1
receptor antagonist in the intercarpal joints of horses. Results showed
improvement in clinical parameters of pain and disease activity, less cartilage
erosion, and decreased loss of proteoglycans in treated horses.
Inducing cells to overexpress BMP-7 has also shown successful results.
Hidaka et al. (2001) used an adenovirus vector encoding for human BMP-7 to
induce cultured bovine chondrocytes to express BMP-7. The results showed
increased proteoglycan and protein synthesis and increased expression of the
cartilage-specific genes for collagen II and aggrecan. When transplanted into
cultured cartilage explants, these chondrocytes were able to form tissue 1.9 times
thicker than that produced by control chondrocytes. In a later study also by
Hidaka et al. (2003) chondrocytes over-expressing BMP-7 were transplanted into
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full-thickness cartilage defects in horses and were able to cause accelerated
healing and a more hyaline-like morphology when compared to controls.

Mesenchymal stem cell transplantation
As described above, mesenchymal stem cells from the bone marrow,
synovium, and periosteum have all been able to undergo chondrocytic
differentiation in culture and in some cases, in vivo. These findings suggest
transplantation of mesenchymal stem cells may be used to repair cartilage defects.
Wakitani et al. (1994) cultured stem cells taken from bone marrow and
periosteum and transplanted them into full-thickness cartilage defects in the knees
of rabbits. The stem cells were able to undergo chondrocytic differentiation and
completely repair the defects in the cartilage and subchondral bone. In a similar
experiment, Grande et al. (1995) transplanted MSCs from muscle into rabbit
knees and achieved comparable results.

Autologous chondrocyte transplantation
Autologous chondrocyte transplantation (ACT) is the process of using a
patient’s own chondrocytes to treat articular cartilage defects. A cartilage biopsy
is taken from a non-weight bearing region in a joint, chondrocytes are isolated
from the cartilage and expanded in monolayer, and the chondrocytes are then
transplanted back into the cartilage defect and sealed with a flap of some sort,
usually periosteal. One of the earliest experiments utilizing this procedure was
performed in rabbits with successful results (Peterson et al., 1984). Brittberg et al.
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(1994) used the same procedure to treat full-thickness cartilage defects in the knee
joints of humans. Patients reported reduced pain and swelling and arthroscopy
showed the transplants grew level with the surrounding cartilage and exhibited
properties of normal hyaline cartilage. Litzke et al. (2004) used Brittberg’s ACT
procedure to treat extensive cartilage defects in horses, demonstrating for the first
time the efficacy of ACT in a large animal model. All sites into which
chondrocytes were transplanted showed filling of cartilage defects level and fully
integrated with the surrounding cartilage and the newly grown cartilage produced
collagen II and other specific markers for the articular cartilage phenotype.
ACT continues to evolve, with different materials being considered for use as a
flap to seal the defect and tissue engineered scaffolds made from biomaterials
gaining use as a means of holding the chondrocytes in the defect area and
enhancing proliferation and differentiation (Marlovits et al., 2006).

Summary
Articular cartilage is a unique tissue that enables the joints to withstand a large
amount of loading while operating in a smooth fashion. The maintenance of
articular cartilage is extremely important for proper joint function and is
controlled by a balance between matrix synthesis and degradation. Often as
patients age or subject their joints to extreme mechanical stress, such as during
heavy exercise, the cartilage loses its ability to maintain the extracellular matrix
and cartilage degradation ensues, leading to osteoarthritis. While there are many
available treatments for osteoarthritis, many have limited effectiveness. Because
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lameness in general and osteoarthritis in particular represent a tremendous loss in
profitability due to veterinary costs, loss of usefulness, and additional labor, it is
vital for the equine industry to find improved ways of treating osteoarthritis that
can be widely available and cost-effective.
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MATERIALS AND METHODS
Lymph Node Preparation
Supramammary lymph nodes were harvested from cows at slaughter (Brown’s
Packing, Gaffney, SC), and fat and other connective tissues were removed. Nodes
were ground with a tabletop meat grinder (Hobart) and frozen at -80ºC. Frozen
node grind was broken into chunks under liquid nitrogen and freeze-dried. The
dried chunks were ground into fine powder using a small food processor and
stored at -80ºC in vacuum-sealed bags.

Working Stock Preparation
A 10%-by weight solution of lymph node extract was prepared by
resuspending lymph node powder in phosphate buffered saline (anhydrous
Na2HPO4, 795 mg/L; KH2PO4, 114 mg/L; NaCl, 9000 mg/L). The solution was
allowed to incubate for 10-20 minutes , followed by centrifugation at 1000 x g for
15 minutes. The top fat layer and bottom precipitate layer were discarded. The
middle fluid layer was saved and heat-inactivated at 60ºC for 60 minutes. Heatinactivated lymph node extract (LNE) was centrifuged at 9000 x g for 30 minutes.
The supernatant was removed and stored at -20ºC. The LNE was filter sterilized
using 0.2 m Acrodisc syringe filters (Pall Corporation, Ann Arbor, MI) prior to
use in cell culture.

Ammonium Sulfate Fractionation
Ammonium sulfate (AS) solutions were prepared by adding AS powder to 10
ml distilled, deionized water and stirring until AS was dissolved. Ten ml of lymph
node working stock was added to the flasks, which were then placed in beakers,
covered with ice, and stirred for 30 minutes. The solutions were transferred to
thick-walled 15 ml conical tubes and centrifuged at 9000 x g for 30 minutes. Each
solution was dialyzed against phosphate buffered saline (PBS) using SnakeSkin®
Pleated Dialysis Tubing (Pierce, Rockford, IL; 7,000 MWCO) until the
osmolarity reached 280-320 mOsm/kg. The osmolarity was measured using a
vapor pressure osmometer.

Protein Assay
The protein concentration of each sample was determined by measuring
absorbance at 260 and 280 with an Eppendorf® Biophotometer. The protein
concentration was calculated by the following formula:
Concentration (mg/ml) = (1.55A280 - 0.76A260) x dilution factor
(Warburg and Christian, 1942)

Each sample was diluted 1:10 – 1:200 with PBS to ensure the concentrations
remained constant across the different dilutions. In addition, the concentrations
were confirmed using a handheld refractometer.

Chondrocyte Harvest
Scapular cartilage was harvested from euthanized adult horses (n=3). Muscle
and connective tissue were removed and cartilage was washed with 70% ethanol.
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Cartilage was minced and transported on ice in medium containing DMEM (with
4.5g/L glucose; without L-glutamine and sodium pyruvate) and 5x antibiotics
(penicillin, 200 units/ml; streptomycin, 200 g/ml; amphotericin, 0.5 g/ml),
followed by overnight digestion with collagenase (1.85 mg/ml), DNase (50
g/ml), and hyaluronidase (50 g/ml) at 37ºC under stirred conditions. Following
digestion, the medium was poured through a cell strainer and centrifuged at 1000
x g for 20 minutes at 23ºC. The cell pellet was resuspended in medium containing
DMEM, 10% bovine growth serum (HyClone, Logan, UT), and 2x antibiotics.
Cells were placed in a 75 cm2 tissue culture flask and incubated at 37ºC (5%
CO2). At confluency, medium was removed, and cells were washed with PBS and
trpsinized. The cell suspension was centrifuged for 20 minutes at 1000 x g. Cells
were counted using a hemacytometer and resuspended to a concentration of 1 x
106 cells/ml in medium containing 50% bovine growth serum (BGS) and 5%
DMSO. Cells were frozen overnight at -80ºC, then stored in liquid nitrogen.

Cell Culture
Cells were thawed and cultured in DMEM, 10% BGS, and 2x antibiotics as
described above. At confluency, cells were washed, trypsinized for 10-15 minutes
at 37ºC, and passaged into 96 well plates at a density of 5000 cells per well (Day
0). On Day 3, medium was removed, cells were washed with PBS, and treatment
medium was added. For Experiment 1, the medium was supplemented with either
0-10% BGS or 0-10% LNE. For Experiment 2, medium was supplemented with
BGS or LNE on an equal protein basis (0.5 mg/ml to 5.0 mg/ml). Treatments for
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Experiment 3 included BGS, LNE, and LNE fractions obtained from 20% or 30%
AS solution precipitation. All media contained an equal protein load (1.5mg/ml).
Finally for Experiment 4, treatments included BGS, LNE, insulin-like growth
factor-1 (IGF-1), and transforming growth factor- (TGF-. Bovine serum
albumin (BSA) was added to medium containing IGF-1 and TGF- to maintain a
protein concentration of 1.0 mg/ml. Concentrations of IGF-1 ranged from 10 to
500 ng/ml and concentrations of TGF- ranged from 0.25 to 20 ng/ml. Treatment
media containing equal amounts of protein were prepared by determining the
desired amount of protein in milligrams and freeze-drying the appropriate volume
of each supplement. Just prior to cell culture, the freeze-dried supplement was
resuspended in DMEM with antibiotics to ensure the volume of DMEM also
remained the same for every treatment. The control medium for all experiments
contained only DMEM and antibiotics. In addition, some wells received no
medium at all on Day 3 so that the cells would rapidly desiccate, die, and serve as
a reference value for the DNA accumulated between Day 0 and Day 3. On Day 7,
treatment medium was removed and plates were stored at -20ºC. Each experiment
was performed with each of the three primary chondrocyte isolates, with multiple
replicates for each treatment.

Measurement of Cell Proliferation
Cell proliferation was measured using the CyQUANT® Cell Proliferation
Assay Kit (Invitrogen, Carlsbad, CA). Cell proliferation results are reported as a
stimulation index calculated by dividing the DNA content of each well at the end
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of culture by the DNA content of the wells that received no medium on Day 3. A
standard curve using known cell numbers was generated each time the assay was
performed to ensure that consistent results were obtained for each assay.

Microscopy
Photographs of cultured cells were taken with a SPOT camera on an Olympus
IMT-2 inverted phase contrast microscope using the 10X and 20X objectives.

Gel Electrophoresis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis was used to
visualize components of each protein sample. Both 15 % and 4-20% gradient gels
were used (Bio-Rad Laboratories, Hercules, CA). Samples containing equal
amounts of protein were diluted 1:2 with Laemmli sample buffer (Bio-Rad
Laboratories, Hercules, CA) containing 5% -mercaptoethanol (2-ME) and boiled
for 3 minutes at 100ºC. Proteins were separated at 170V for 30-40 minutes.
Following electrophoresis, the gels were washed 3 times for 15 minutes each with
nanopure water then stained with Gel Code Blue Stain Reagent (Pierce, Rockford,
IL).

Statistical Analysis
Results were analyzed using SAS (SAS Institute, Cary, NC) PROC MIXED
ANOVA to evaluate effects of treatment, concentration, and the interaction
between treatment and concentration for each experiment. P values were adjusted
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using the Sidak procedure to control experimentwise error rate. The Sidak
adjustment utilizes the following equation:
Adjusted p-value = 1 – (1- unadjusted p-value) k where k = number of
comparisons
(Sidak, 1967)

Additionally, effects of date and horse were analyzed to ensure no significant
differences existed between experiments conducted on different days or with
chondrocytes isolated from difference horses.  was set at 0.05.
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RESULTS

Protein Assay
The protein concentration of each supplement was measured so that treatment
media could be normalized for protein load. The protein concentration of BGS
was 68.0 mg/ml ± 4.2 (SEM), and the protein concentration of LNE was 23.6
mg/ml ± 0.9 (SEM). The protein concentrations of ammonium sulfate fractions
were 2.9 mg/ml ± 0.2 (SEM) and 2.2 mg/ml ± 0.3 (SEM), for 20% AS and 30%
AS, respectively.

Experiment One: BGS vs. LNE - Unequal Protein Basis
Cell proliferation in response to treatment with media containing 0-10% (v/v)
BGS and LNE was investigated. Cells cultured in medium containing greater than
5% BGS did exhibit greater proliferation than those receiving control medium,
but cell proliferation in response to treatment with LNE was not different from the
control at any concentration. Additionally, there was no significant difference in
cell proliferation between cells cultured with BGS and cells cultured with LNE at
any concentration. (Fig. 1)
Cultured chondrocytes had an elongated cobblestone-like appearance and
exhibited expanded nuclei and prominent nucleoli. Cell morphology remained
consistent over all concentrations of BGS and most concentrations of LNE (Fig.
2A-C). Cells receiving the highest LNE concentrations (>9%) showed a dramatic

change in morphology (Fig. 2D). They became more rounded with less prominent
nuclei and a darker, somewhat grainy appearance.
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Figure 2: Morphology of cells receiving BGS or LNE. Panels A and B depict cells receiving
medium containing 5% BGS and 10% BGS.Panels C and D depict cells receving medium
containing 5% LNE and 10% LNE. (10X objective)

Experiment Two: BGS vs. LNE – Equal Protein Basis
In the previous experiment, cell proliferation in response to treatment media
containing BGS and LNE on a volume/volume basis was investigated. Because of
the substantial difference in protein concentration between BGS and LNE, the
next experiment compared cell proliferation in response to treatment media
containing BGS and LNE on an equal protein basis. No significant difference in
proliferation was found between cells receiving BGS and those receiving LNE at
any concentration (Figure 3). Additionally, there was no difference in
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proliferation between cells cultured in the control medium and cells cultured in
treatment media at any concentration.

BGS vs. LNE - Equal Protein
3.0

BGS
LNE

Stimulation Index

2.5
2.0
1.5
1.0
0.5
0.0
0

0.5

1.0

1.5
2.0
2.5
3.0
3.5
Protein Concentration (mg/ml)

4.0

4.5

5.0

Figure 3: Bovine Growth Serum vs. Lymph Node Extract – Equal Protein Basis

Experiment 3: BGS and LNE vs. LNE fractions from precipitation with 20% and
30% ammonium sulfate – equal protein basis
Cells cultured in treatment media containing LNE fractions from ammonium
sulfate precipitation were compared to cells cultured in media containing BGS
and LNE to determine if certain LNE fractions possessed factors more likely to
stimulate or inhibit cell proliferation. Cells receiving LNE at 1.5 mg/ml exhibited
greater proliferation than cells receiving BGS or either AS fraction on an equal
protein basis [Adj. p (Sidak) < 0.05] (Fig. 4) When comparing just the AS
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fractions over a range of protein concentrations (0.5 mg/ml – 1.5 mg/ml), there
was no difference in proliferation between the 20% fraction and the 30% fraction
at any concentration (Fig. 5). However, cells cultured in media containing the
20% AS fraction at 0.5 mg/ml and 1.0 mg/ml and the 30% AS fraction at 0.5
mg/ml showed a significant increase in proliferation over cells cultured in the
control medium.
Cells receiving BGS or AS fractions exhibited the same elongated,
cobblestone-like morphology described previously. (Fig. 6A, C, D) Cells
receiving LNE were more rounded and less spread out than the others. (Fig. 6B)

BGS, LNE, AS Fractions - Equal Protein
3.0

*

Stimulation Index

2.5
2.0
1.5
1.0
0.5
0.0
0

BGS

LNE
20% AS
Medium Supplement

30% AS

*

denotes a difference between the designated concentration and all other
concentrations [Adj. P (Sidak) < 0.05]

Figure 4: BGS and LNE vs. LNE fractions from precipitation with 20% or 30%
ammonium sulfate. Equal protein basis (1.5 mg/ml).
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20% AS vs. 30% AS
20% AS
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Figure 5: LNE fractions from precipitation with 20% or 30%
ammonium sulfate over a range of protein concentrations. Equal protein basis (0 –
1.5 mg/ml).
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Figure 6: Cultured cell morphology. Panel A depicts cells receiving BGS, Panel B
depicts cells receiving LNE, and Panels C and C depict cells receiving LNE fractions
from precipitation with 20% ammonium sulfate and 30% ammonium sulfate,
respectively. (20X objective)

Experiment 4 – Supplementation with IGF-1 and TGF-
IGF-I and TGF- are often added to chondrocyte culture media. Cell
proliferation in response to culture in media containing IGF-I and TGF- was
investigated. There was no difference in cell proliferation between any of the
IGF-1 concentrations (Fig.7). Additionally there was no difference in proliferation
between cells receiving IGF-1 and those receiving control medium, or between
cells receiving IGF-1 and those receiving medium supplemented only with BSA.
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Cell proliferation was also compared to that from cells receiving 1 mg/ml BGS or
LNE, since IGF-1 treatment medium also contained 1 mg/ml BSA. There was no
difference in proliferation between cells receiving any concentration of IGF-1 and
those receiving 1 mg/ml of either BGS or LNE.
There was no difference in cell proliferation between any concentrations of
TGF-and no overall effect of supplementation with TGF- (; Fig.8)
dditionally, there was no difference in proliferation between cells receiving
TGF- and those receiving control medium or medium supplemented only with
BSA, nor was there any difference in proliferation between cells receiving TGF-
and those receiving 1 mg/ml of either BGS or LNE.
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BSA designates cells that received medium supplemented with BSA only

Figure 7: Cell proliferation in response to IGF-1
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Transforming Growth Factor Beta
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Figure 8: Cell proliferation in response to TGF-.

Gel Electrophoresis
There did not appear to be bands present in either BGS or LNE that
disappeared after precipitation with 20% or 30% AS. All four samples showed
heavy dark bands between 50 and 75 kDa and others at 25 and 10-15 kDa.
However, the 20% and 30% AS fractions had darker bands present in the lower
molecular weight range (< 50 kDa) than either BGS or LNE (Fig. 9) Bands less
than 25 kDa were almost indistinguishable for BGS and were very light for LNE.
Gradient gels showed many dark bands in the 10 – 15 kDa region rather than one
band darker than the others as seen in the 15% gel (Fig. 10). Protein load was
approximately the same in each lane.
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Figure 9: 15% polyacrylamide gel of BGS, LNE, and LNE fractions
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Figure 10: 4-20% polyacrylamide gradient gel of BGS, LNE, and LNE
fractions.

44

DISCUSSION
The results suggest LNE is capable of stimulating cell proliferation to an equal
or greater degree than BGS. For Experiment 1, which compared BGS and LNE on
a volume/volume basis, results indicate no difference in cell proliferation between
cells receiving medium supplemented with BGS and medium supplemented with
LNE. Considering the respective protein values of BGS and LNE (68.0 mg/ml ±
4.2 and 23.6 mg/ml ± 0.9), a greater increase in proliferation in response to BGS
compared to that of LNE would have been expected. The fact that LNE managed
to perform reasonably well against BGS, even at a much lower protein
concentration, suggests there may be growth factors present in LNE capable of
stimulating cell proliferation to a greater degree than those present in BGS.
However, the change in cell morphology which occurred at higher levels of LNE
supplementation may also indicate the presence of factors which are detrimental
to the cells at higher concentrations. A similar change in morphology occurred in
preliminary experiments utilizing non-heat inactivated LNE and was accompanied
by decreased proliferation and cell death.
Experiment 2 compared BGS and LNE on an equal protein basis to correct the
large difference in protein concentration occurring when the culture medium was
supplemented with BGS or LNE on a volume/volume basis. Results from
Experiment 1 suggested that LNE may be capable of stimulating increased
proliferation than BGS when protein concentrations of both were equal. However,
the results from Experiment 2 did not support this hypothesis. When BGS and

LNE were compared across a range of protein concentrations, there was no
difference between treatments at any concentration. There also was no significant
effect of increasing protein concentrations within either treatment. However, these
results may be inconclusive. Figure 3 indicates that the average proliferative
response to LNE was much higher at some concentrations than BGS, but there
was also a great deal of variation, causing the differences to be insignificant.
Experiment 2 was conducted on one day only and there was much more variation
within treatments than had occurred for any other experiment on any other day.
Cells from only two horses were used, and there were fewer replicates within each
treatment. Cell culture, media preparation, and proliferation assays were
conducted in the same manner as for every other experiment. If the experiment
was conducted again with more replications and included cells from the third
horse, more consistent results could be obtained.
Experiment 3 compared the response to BGS and LNE with the response to
LNE fractions from precipitation with 20% and 30% AS. Precipitation was not
carried out with greater than 30% AS because preliminary experiments showed no
difference between 30% AS and other subsequent fractions. 1.5 mg/ml was
arbitrarily chosen as the protein concentration used because it was the highest
common dilution that could be achieved with all four samples based on the
protein quantity recovered that day from the precipitation procedure. Results from
Experiment 3 showed significantly higher cell proliferation in response to
treatment with LNE [Adj. p (Sidak) < 0.05]. Cell proliferation was not different
among cells receiving BGS or either AS fraction, and none of the these three
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treatments resulted in proliferation different from the control. The difference
between BGS and LNE supports the conclusion from Experiment 1 that LNE may
induce greater proliferation than BGS on an equal protein basis. The increased
response to LNE was also expected in Experiment 2. Experiment 3 was conducted
on two different days with chondrocytes from all three horses and fourteen
replicates per treatment. The results obtained in Experiment 3 suggest that LNE
may be capable of inducing increased proliferation, despite the results of
Experiment 2. However, cells receiving LNE did exhibit a change in morphology.
While not as pronounced as the change in morphology occurring in cells receiving
high concentrations of LNE in Experiment 1, this change in morphology indicates
that, in addition to increased proliferation, the cells respond differently to LNE
than to the other treatments.
The difference in proliferation between LNE and the two AS fractions could
indicate that proteins involved in stimulating cell proliferation were lost during
the fractionation procedure. It could also indicate that the precipitation procedure
resulted in an increased concentration of suppressive factors in the AS fractions.
The response could also come from the combined effect of proteins lost,
interactions between different proteins, and increased concentrations of proteins
left in the fractions. Gel electrophoresis showed no obvious disappearance of
bands after LNE fractionation but did show darker bands in the lower molecular
weight region, indicating increased concentrations of those proteins. Since many
growth factors tend to have lower molecular weights, there may be increased
concentration of growth factors in the fractions. However, since there was no
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increase in proliferation in response to either fraction, this may not be the case.
There may also be a greater concentration of suppressive factors.
When comparing just the two AS fractions over a range of concentrations,
there was no difference in proliferation between cells receiving either fraction.
However, lower concentrations of both fractions resulted in increased
proliferation over the controls, indicating that there are still factors present in the
fractions capable of stimulating cell proliferation. However, as the protein
concentration of both fractions increased, cell proliferation decreased, although
not significantly so. Nevertheless, decreased proliferation could indicate an
increased concentration of suppressive factors in the AS fractions.
Experiment 3 would have been carried out over a greater range of protein
concentrations, 0.5 – 5.0 mg/ml rather than just 0.5 to 1.5 mg/ml, but media
contamination was a problem. All treatments were filter-sterilized just prior to cell
culture, but cells receiving medium supplemented with AS fractions became
contaminated with bacteria nearly every time the experiment was carried out.
Cells receiving other treatments were never affected, and the source of
contamination was never identified.
Experiment 4 tested the effects of supplementing the culture medium with
IGF-1 or TGF-These two growth factors were selected because they have often
been used to stimulate chondrocyte proliferation, differentiation, and cartilage
matrix synthesis (Chaipinyo et al., 2002; Darling and Athanasiou, 2005; Jakob et
al. 2001; Pei et al. 2002; Worster et al., 2001) Results showed no effect on
proliferation in response to either growth factor. No concentration of either factor
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resulted in proliferation different from the control, although proliferation did
appear to decrease slightly with increased concentration, but not significantly so.
The concentrations of IGF-1 and TGF- were selected based on published
concentrations of each factor used to stimulate chondrocytes in vitro. A range of
concentrations from much lower to much higher than the published concentrations
was used for each treatment. Additionally, treatment media contained 1 mg/ml
BSA to act as a protein source since all other treatments contained protein from
BGS or LNE. There was no difference in proliferation among cells receiving
either growth factor, medium containing only BSA, and control medium. There
also was no difference in proliferation between cells receiving any of the latter
and those receiving 1 mg/ml BGS or LNE. These results indicate that none of
these treatments are capable of stimulating cell proliferation.
Just because treatments are not stimulating proliferation does not mean they do
not have any effect on the cells at all. In many instances, IGF-1 and TGFstimulate production of collagen and aggrecan rather than stimulating
proliferation. Differentiated chondrocytes that are producing matrix components
do not tend to proliferate. In many cases increased proliferation is seen as a sign
of dedifferentiation (Aulthouse et al., 1989; Archer et al., 1990; Schnabel et al.,
2002). It is possible that cells not proliferating in response to these different
treatments may be differentiated and trying to produce matrix components.
However, chondrocytes cultured in monolayer often become dedifferentiated
(Aulthouse et al., 1989; Archer et al., 1990; Schnabel et al., 2002) so this may not
be the case. As a point of interest, cells exposed to LNE (>1.5 mg/ml) developed a
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more rounded morphology which is often associated with the differentiated
phenotype (Kolettas et al., 1998) The production of collagen II and aggrecan by
these cells would confirm that they have remained differentiated, while the
absence of these would indicate a return to a dedifferentiated, fibroblastic state.
Conclusion
Overall, LNE was capable of stimulating chondrocyte proliferation to an equal
or greater degree than BGS, as shown in three experiments. Further studies are
needed to determine if certain LNE fractions possess greater mitogenic activity
than the whole nodal extract. Gene expression studies would show whether or not
chondrocytes treated with LNE retain their phenotype. Additional experiments
investigating proliferation of chondrocytes cultured in a three dimensional matrix
versus monolayer and proliferation of chondrocytes passaged directly into
medium containing LNE without the three-day adjustment period could provide
more insight as well. However, bovine serum is the most tested and tried,
commonly used supplement for cell culture medium, and LNE was able to
stimulate cell proliferation to the same or greater extent. These results alone
suggest LNE could promote cartilage healing and has the potential to be used in
developing new therapies for osteoarthritis in horses.
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APPENDIX
CyQUANT Standard Curve

A standard curve, created from known chondrocyte numbers, was generated
each time the CyQUANT assay was performed. Figure 1 shows the standard
curve generated for each of 45 separate assays. The trend line shown is based on
the average fluorescence output seen for each known quantity of cells.

Figure A-1: CyQUANT assay standard curve based on known chondrocyte numbers. The
vast majority of observations recorded for cultured cell samples fell within the boxed
portion of the curve, where linearity was most consistent.
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